|George R. Siber, MD is an internationally recognized vaccine expert with 38 years of experience in developing numerous innovative vaccines, therapeutic antibodies and diagnostic agents for infectious diseases. |
From 1975 to 1996, Dr Siber served on the Faculty of Medicine at Harvard University as Assistant and Associate Professor of Medicine based at the Dana Farber Cancer Institute. Concurrently, from 1982 to 1996, Dr Siber was Director of the Massachusetts Biologic Laboratories, a public sector laboratory which manufactures licensed vaccines and immune globulins (antibodies) for the state of Massachusetts. Under his leadership the laboratory developed specific immune globulins to CMV (Cytogam) and to RSV (Respigam) the precursor product to Synagis, both of which were licensed to MedImmune. Synagis was the first therapeutic monoclonal antibody licensed for an infectious disease and has sales over $1B per year.
From 1996 to 2007, Dr. Siber was Executive Vice President and Chief Scientific Officer of Wyeth Vaccines Research, overseeing a staff of 800 scientists in the development, approval and marketing of six innovative childhood vaccines including Prevenar, the first pneumococcal conjugate vaccine, Meningitec, the first Meningococcal C conjugate vaccine, Rotashield, the first rotavirus vaccine and FluMist, the first live nasal influenza vaccine. Prevenar has dramatically reduced the burden of pneumococcal disease in the countries that have introduced it and has become the largest selling vaccine of all time (more than $3 Billion per year). Dr Siber is co-inventor of the patent for the formulation of Prevenar 13 which is expected to reach sales of more than $5 Billion per year.
Dr Siber is currently Chief Scientific Officer of ClearPath Vaccines Company a vaccine development company which is focused on developing novel vaccines with high medical need.
Dr Siber currently also serves on the Board of Directors of Genocea Biosciences (as Executive Chairman), Selecta Biosciences and Vedantra, all vaccine companies founded by scientists from Harvard University and/or the Massachusetts Institute of Technology (MIT). He also serves on the Scientific Advisory Boards of Prothena, AbVitro and Visterra.
Dr. Siber has served on numerous US government and international advisory committees, including the World Health Organization, the Pan American Health Organization, the Institute of Medicine, the National Institutes of Health, PATH, the Bill and Melinda Gates Foundation, the European Commission, the Korean FDA, the Advisory Committee of the Canadian Pan-Provincial Vaccine Enterprise and the external Advisory Board of ADITEC. Dr Siber also served on the Council of NIAID.
Dr. Siber received his medical degree from McGill University in Montreal, Canada. He trained as a medical intern and resident at Rush-Presbyterian Medical Center in Chicago, Illinois, and as a senior medical resident at Beth Israel Hospital, Harvard Medical School, Boston. Dr. Siber completed clinical and research fellowship training in infectious diseases and vaccinology at Beth Israel Hospital and Children’s Hospital at Harvard Medical School in the laboarories of Porter Anderson and David Smith. He is currently Adjunct Professor of Medicine at Johns Hopkins Medical School.